MedTrace Logo

Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study

NCT04724941 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-09-22

No results posted yet for this study

Summary

The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.

Conditions

  • Parkinson Disease

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • UCB Biopharma SRL

    collaborator INDUSTRY

  • University of Kiel

    collaborator OTHER

  • University Hospital Schleswig-Holstein

    lead OTHER

Principal Investigators

  • Daniela Berg, Prof.Dr. · Department for Neurology, University of Kiel

Eligibility

Min Age
50 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04724941 on ClinicalTrials.gov